header advert
Results 1 - 3 of 3
Results per page:
Applied filters
General Orthopaedics

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 98-B, Issue SUPP_10 | Pages 40 - 40
1 May 2016
Wessell N Frisch N Charters M Cann B Greenstein A Silverton C
Full Access

Perioperative blood management remains a challenge during total hip and total knee arthroplasty (THA and TKA, respectively). The purpose of this study was to determine the impact of body mass index (BMI) on blood transfusion in THA and TKA. We retrospectively evaluated 2399 patients, of whom 896 underwent THA and 1503 had TKA. A variety of outcome variables were assessed for their relationship to BMI which was stratified using the World Health Organization (WHO) classification scheme (Normal <25 kg/m2, Overweight 25–30, and Obese >30). Increased BMI was found to be protective of blood transfusion in both THA and TKA patients. Among THA patients, transfusion rates were 34.8%, 27.6% and 21.9% for normal, overweight and obese categories respectively (p = 0.002). TKA transfusion rates were 17.3%, 11.4% and 8.3% for the same categorization of BMI (p = 0.002). No trends were identified for a relationship between BMI and deep vein thrombosis, pulmonary embolism, myocardial infarction, discharge location, length of stay, 30-day readmission rate and preoperative hemoglobin level. Elevated BMI was significantly associated with decreased age, increased Hemoglobin A1c, increased baseline creatinine, increased OR time, increased American Society of Anesthesiologists (ASA) score and increased estimated blood loss in both THA and TKA patients. There was a statistically significant trend toward increased deep surgical site infection in THA patients (p = 0.043).


Orthopaedic Proceedings
Vol. 98-B, Issue SUPP_7 | Pages 141 - 141
1 May 2016
Frisch N Wessell N Van Holsbeeck M Silverton C
Full Access

Introduction

The use of metal-on-metal (MOM) and modular total hip arthroplasty (THA) is associated with potentially serious complications including elevated serum metal ion levels, pseudotumor, cardiomyopathy and neurologic abnormalities. The primary aim of this analysis was to identify any associations between the presence of pseudotumor, serum metal ion levels, and specific dual modular implant components.

Methods

We evaluated prospectively collected data from 49 patients, mean age 58.4 years, who underwent implantation of modular THA from 01/2004-01/2010. The collected data spanned a 5–11 year period from the time of index procedure. Serum metal ion levels, including titanium, cobalt and chromium, were collected in 2012 and 2015. Hip ultrasounds were performed on each patient by a trained musculoskeletal radiologist for evaluation of the presence of soft-tissue pseudotumor. Univariate nonparametric tests were used to compare the two groups: Fisher's exact tests for categorical variables, and Wilcoxon two-group tests for continuous variables. For the purposes of analysis, values that were below the level of detection (LOD) were set to half the LOD. All analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA). Statistical significance is set at p<0.05.


Orthopaedic Proceedings
Vol. 95-B, Issue SUPP_34 | Pages 60 - 60
1 Dec 2013
Frisch N Charters M Wessell N Sikora-Klak J Dobson C Yu S Silverton C Laker M Les C
Full Access

Purpose:

Starting February 2012, our institution changed from enoxaparin (Lovenox) to the Factor Xa inhibitor, rivaroxaban (Xarelto) for venous thromboembolism prophylaxis after primary total hip (THA) and total knee arthroplasty (TKA). The purpose of our study was to compare rates of venous thromboembolism and rates of major bleeding between these two medications when used for venous thromboembolism prophylaxis after primary THA and TKA.

Methods:

A retrospective review was performed on 1795 patients who underwent THA or TKA at our institution between January 1, 2011 and December 31, 2012. Patients were excluded if they had a bilateral procedure, partial arthroplasty (hip hemiarthroplasty, unicompartmental knee arthroplasty), revision surgery, and cases designated as complex. Patients were excluded if they were on other anticoagulants (dabigatran, aspirin, clopidogrel, warfarin, heparin, fondaparinux), or if pre-operative creatinine was 1.2 or greater. After excluding these patients, there were 1089 patients included in the study. Chart review recorded demographics (age, gender), comorbidities (BMI, ASA, creatinine), surgery performed (primary THA or TKA), length of stay (LOS), venous thromboembolic events (deep venous thrombosis [DVT], pulmonary embolus [PE]), post-operative infections, and major bleeding events (stroke, post-operative bleeding requiring transfusion). Periprosthetic infection rates are also currently being reviewed. T-tests were used to compare continuous variables between treatment groups, and Chi-square tests were used to compare categorical variables between treatment groups (α = 0.05).